James B Fink, PhD, RRT, FAARC, FCCP, Aerogen Pharma Corp. - Qepler Summits And Conferences

James B Fink, PhD, RRT, FAARC, FCCP

Chief Scientific Officer
Aerogen Pharma Corp.
San Mateo, CA, USA
Aerosol Drug Delivery To The Lungs | Aerogen Pharma - Inspired to create a new standard for aerosol drug delivery to the lungs, for the improved care of patients receiving ventilatory support in the ICU.

Currently Chief Science Officer for Aerogen Pharma Corporation, San Mateo, CA.

Dr. Fink serves as Adjunct Professor for the Respiratory Therapy Program at Texas State University in Round Rock, Texas, Rush Medical School in Chicago, IL, and Visiting Professor, Department of Physical therapy, Universidade Federal de Pernambuco, Recife, Brazil. Jim has a PhD in Pharmaceutical Innovation from Bradford University, UK. Previously Dr. Fink was Fellow of Respiratory Science at Nektar Therapeutics and Aerogen Ltd. developing novel aerosol delivery systems for critically ill adults and infants with more than 40 issued patents, and 200+ peer reviewed papers. He is a member of the International Society of Aerosols in Medicine and co-chair of their upcoming Congress in Boise, ID, in May 2021.

Jim is a Fellow of the American Association for Respiratory Care and the American College of Chest Physicians and was awarded the 2017 Forest M. Bird Lifetime Scientific Achievement award from the American Respiratory Care Foundation.

Related Sessions:

2nd Annual Inhaled
Drug Delivery Summit 2021

Assess and harness novel approaches to the development of inhaled drug products for enhanced patient care.
  • 05 Aug 2021
  • Virtual,
  • Pharma
Day 1: Thursday, 05 August 2021
CASE STUDY: Transnasal Pulmonary Drug Delivery in Acute and Critical Care – Practice to Promise..
  • Administration of medical aerosols to the lung of our sickest patients has multiple challenges in the critical care environment including the need to not interrupt oxygen and ventilatory support.
  • Aerosol delivery via High Flow Nasal Oxygen is used by >70% of intensivists worldwide for a variety of applications, with expanding knowledge of best practices of optimal delivery efficiency achieving double digit delivery efficiency in both preterm infants and adults.
  • Knowable and controlable, transnasal pulmonary aerosol delivery has the promise of efficient and consistent administration of a wide range of formulations supporting development and approval of inhaled medications for management of the critically ill.
View Details